12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients-Reference-Cited by-同舟云学术

12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients

Published:2007-01 Issue:1 Volume:20 Page:27-36
ISSN:0934-0874
Container-title:Transplant International
language:en
Short-container-title:Transplant Int

Author:

Tedesco-Silva Helio,Vitko Stefan,Pascual Julio,Eris Josette,Magee John C.,Whelchel John,Civati Giovanni,Campbell Scott,Alves-Filho Gentil,Bourbigot Bernard,Garcia Valter Duro,Leone John,Esmeraldo Ronaldo,Rigotti Paolo,Cambi Vincenzo,Haas Tomas,

Publisher

Frontiers Media SA

Subject

Transplantation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1432-2277.2006.00414.x/fullpdf

Reference21 articles.

1. Post-transplant renal function in the first year predicts long-term kidney transplant survival

2. Strategies to Improve Long-Term Outcomes after Renal Transplantation

3. Early Clinical Experience With a Novel Rapamycin Derivative

4. Rapamune (Sirolimus, Rapamycin): An Overview and Mechanism of Action

5. SDZ RAD, A NEW RAPAMYCIN DERIVATIVE

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2022-08

2. An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients;Transplantation Reviews;2021-09

3. Real-World Efficacy and Safety of Everolimus with Low Dose Tacrolimus in Liver Transplantation Recipients;Korean Journal of Clinical Pharmacy;2021-03-31

4. An open-label randomized clinical trial to evaluate the efficacy of everolimus versus tacrolimus in triple maintenance immunosuppressive therapy for kidney transplant patients;Brazilian Journal of Medical and Biological Research;2021

5. Comparison of Kidney Transplant Function, Lipid Metabolism Disorders, and Glucose and Hemoglobin Concentration in Transplant Patients Treated With Proliferation Signal Inhibitor (Everolimus) or Calcineurin Inhibitor (Tacrolimus);Transplantation Proceedings;2020-10